Try a new search

Format these results:

Searched for:

person:nachtr01

in-biosketch:true

Total Results:

20


Femarelle (R), a Novel SERM for the Treatment of Menopause. Did Not Affect the Clotting Time of Either Normal or Thrombophilic Postmenopausal Women [Meeting Abstract]

Nachtigall, M; Nachtigall, L; Nachtigall, R; Yoles, I; Flaumenhaft, R
ISI:000260858500125
ISSN: 1072-3714
CID: 90945

Clot formation assay in postmenopausal women receiving either oral or transdermal estrogen therapy [Meeting Abstract]

Nachtigall, Margaret J.; Nachligall, Lisa B.; Nachtigall, Richard H.; Lowenstein, Joanna; Nachtigall, Lila E.; Flaumenhaft, Robert C.
ISI:000246801600185
ISSN: 0029-7844
CID: 720872

Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy

Nachtigall MJ; Smilen SW; Nachtigall RD; Nachtigall RH; Nachtigall LE
OBJECTIVE: To review the incidence of breast cancer in a continuous 22-year study of conjugated estrogen-medroxyprogesterone acetate hormone replacement therapy. METHODS: Eighty-four pairs of continuously hospitalized postmenopausal women who were matched for age, smoking history, and medical diagnosis were treated with estrogen-progestin hormone replacement therapy or placebo in a prospective and double-blind manner for 10 years. In the subsequent 12 years, the women were offered the choice of starting, stopping, or continuing hormone replacement therapy. RESULTS: After the initial 10 years, the incidence of breast cancer in the placebo group was 4.8%, whereas no cancers were found in the hormone replacement therapy group (P = .12). After an additional 12 years of follow-up, the overall incidence of breast cancer in the women who had never taken hormone replacement therapy was 11.5%, whereas no breast cancers had developed in the women who had ever taken hormone replacement therapy (P < .01). CONCLUSIONS: These data suggest that the 22-year administration of estrogen-progestin hormone replacement therapy did not increase the incidence of breast cancer in a small group of continuously hospitalized postmenopausal women
PMID: 1328978
ISSN: 0029-7844
CID: 57462

Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems

Nachtigall LE; Nachtigall RH; Nachtigall RD; Beckman EM
A 10-year double-blind prospective study was undertaken to evaluate the effects of estrogen replacement therapy (ERT). The sample population consisted of 84 pairs of randomly chosen postmenopausal in-patients, matched for age and diagnosis. The treatment group received high-dose conjugated estrogens, cyclically with progesterone. The controls recieved placebos. Results revealed no statistically significant difference in that incidence of thrombophlebitis, myocardial infarction (MI), or uterine cancer. There was a lower incidence of breast cancer in the treated group. Estrogen-treated patients showed a higher incidence of cholelithiasis. Those in the treated group who began the study with elevated beta/alpha lipoprotein ratios showed a reduction in that ratio over the course of the study, while the controls either maintained or increased their ratios. The low number of cases precludes drawing any real significance from the data on diseases of low frequency. The study excludes only a high incidence of complications from estrogens
PMID: 221871
ISSN: 0029-7844
CID: 18784

Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis

Nachtigall LE; Nachtigall RH; Nachtigall RD; Beckman EM
A 10-year, double-blind prospective study was undertaken to evaluate the effects of estrogen replacement therapy. The sample population consisted of 84 pairs of randomly chosen postmenopausal patients who were matched for age and diagnosis. One half of the patients received conjugated estrogens and cyclic progesterone, while the other half received placebo. Estrogen-treated patients whose therapy started within 3 years of menopause showed improvement or no increase in osteoporosis. Control patients demonstrate an increase in their osteoporosis
PMID: 218151
ISSN: 0029-7844
CID: 18785

Serum immunoreactive relaxin concentrations in human pregnancy, labor and the puerperium

Quagliarello, J; Nachtigall, R; Goldsmith, L T; Hochman, J; Steinetz, B G; O'Bryen, E M; Weiss, G
PMID: 463632
ISSN: 0065-2598
CID: 105272

[Comparison of findings between children with short-term and long-term epileptic attacks]

Wasser, S; Quick, G; Nachtigall, R
PMID: 826030
ISSN: 0044-2178
CID: 810212

ESTROGENS AND ENDOMETRIAL CARCINOMA - REPLY [Letter]

Nachtigall, LE; Nachtigall, RH; Nachtigall, RB; Beckman, EM
ISI:A1976BL82800028
ISSN: 0028-4793
CID: 29486

Treatment of familial dysautonomia with bethanecol (urecholine)

Axelrod FB; Branom N; Becker M; Nachtigall R; Dancis J
PMID: 5049832
ISSN: 0022-3476
CID: 43363

Hemorrhagic cysts of thymus

Missier, P A; Kreps, S; Nachtigall, R H; Jaspin, G; Fischer, W W
PMID: 5285476
ISSN: 0028-7628
CID: 423282